Improved outcomes with early immunosuppression in patients with immune-checkpoint inhibitor induced myasthenia gravis, myocarditis and myositis: a case series
Authors:
- 12 August 2023
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 31 (9) , 1-6
Abstract
Purpose Myasthenia gravis (MG) is a rare but life-threatening complication of immune-checkpoint inhibitor (ICI) therapy and often co-presents with myositis and myocarditis. Previous case series of ICI-related MG have reported high mortality rates. We present a series of ten patients from a tertiary oncology centre outlining outcomes of an early multi-modal immunosuppression strategy. Methods We reviewed The Christie Hospital database of immunotherapy-related toxicity from 2017 to 2020. Symptom severity was assessed using the Myasthenia Gravis Foundation of America (MGFA) classification. Results Ten patients with ICI-related MG were identified. All patients presented following 1 (n = 4) or 2 (n = 6) cycles of ICI. Symptom progression was rapid with a median of 3 days from onset of symptoms to admission. Concomitant myositis and myocarditis were observed in nine patients. AChR or MuSK autoantibodies were positive in six patients. All patients received urgent treatment with intravenous methylprednisolone (IVMP) and eight received intravenous immunoglobulin (IVIG). A single patient died from myasthenia-related symptoms; the remaining 9 patients were successfully discharged. Conclusion In our cohort, we demonstrate good outcomes associated with early intensive immunosuppressive treatment with IVIG and IVMP. An agreed national treatment protocol or clinical discussion forum would be beneficial.Keywords
This publication has 9 references indexed in Scilit:
- Immune Checkpoint Inhibitor–Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of CasesThe Oncologist, 2021
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse eventsJournal for ImmunoTherapy of Cancer, 2021
- International Consensus Guidance for Management of Myasthenia GravisNeurology, 2021
- Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS databaseJournal of Neuro-Oncology, 2021
- Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitorsSupportive Care in Cancer, 2020
- Emergency presentations in patients treated with immune checkpoint inhibitorsEuropean Journal of Cancer, 2020
- Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literatureJournal for ImmunoTherapy of Cancer, 2019
- Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance studyJournal for ImmunoTherapy of Cancer, 2019
- Nivolumab-related myasthenia gravis with myositis and myocarditis in JapanNeurology, 2017